Background
==========

Cholangiocarcinoma, a rare form neoplasm originating from the intra- or extra-hepatic bile duct epithelium, accounts for about 3% of gastroenteric tumors and is the second most common primary hepatic neoplasia \[[@b1-medscimonit-21-2375],[@b2-medscimonit-21-2375]\]; however, its incidence rate is increasing \[[@b3-medscimonit-21-2375]\]. Cholangiocarcinoma is also one of the most common cancers in China \[[@b4-medscimonit-21-2375]\]. Surgical resection is the only curative approach \[[@b3-medscimonit-21-2375]\]; however, due to delayed diagnosis, resection rates are low.

Although some patients undergo surgical therapy, the recurrence rate in those patients is very high \[[@b5-medscimonit-21-2375],[@b6-medscimonit-21-2375]\]. The poor prognosis is dependent on a multitude of factors, including tumor differentiation, tumor staging, lymph node metastasis, nerve invasion, intravascular cancer emboli, the depth and distribution of infiltration, tumor size, successful tumor resection, and location of tumor. It has been shown that perioperative blood transfusion is a strong predictor of poor survival after radical hepatectomy for hilar cholangiocarcinoma \[[@b7-medscimonit-21-2375]\]. Another study showed that a positive resection margin is associated with poor overall survival in peripheral cholangiocarcinoma patients undergoing hepatectomy \[[@b8-medscimonit-21-2375]\]. In a population-based study, poor performance status, primary tumor location, and sites of advanced disease were found to be relevant to prognosis \[[@b9-medscimonit-21-2375]\]. Furthermore, patients with unresectable cholangiocarcinoma have limited treatment options with only modest survival advantages \[[@b10-medscimonit-21-2375],[@b11-medscimonit-21-2375]\].

All of the aforementioned indices can thus be important indicators for chemotherapeutic decision-making post-surgery. Hence, investigating biological characteristics of cholangiocarcinoma and the associated factors that would inform successful therapeutic regimen is of paramount importance.

Material and Methods
====================

Patients
--------

The study was approved by the Institutional Review Board of the General Hospital of the Chinese PLA, Beijing, China. Between 2004 and 2010, a total of 397 consecutive patients diagnosed with cholangiocarcinoma underwent surgery in the General Hospital of the Chinese PLA. Of the 397 patients, a total of 293 had follow-up results available and were enrolled in the current study.

Statistical analyses
--------------------

Unless designated otherwise, results are presented as mean ± standard error of mean (SEM). SPSS19.0 software was used for data analysis. Log-rank test was used for single-factor analysis and Cox regression analysis was used for multivariable survival analysis. P\<0.05 was considered statistically significant.

Results
=======

The 293 enrolled patients included 202 men and 91 women (average 64 years old) with age of onset of cholangiocarcinoma ranging between 40 and 85 years. The clinicopathological characteristics of the enrolled patients are summarized in [Table 1](#t1-medscimonit-21-2375){ref-type="table"}. The peak of the onset age was from 50 to 60 years old. Men were comparatively more predisposed to cholangiocarcinoma than females (sex ratio of male to female ranged from 1.5 to 3.0). There were 74 and 219 cases of intra- and extrahepatic tumors, respectively. Classified according to TMN stage, there were 150 in stage 1, 88 in stage 2, 41 in stage 3, and 14 in stage 4. There were 19 cases of well-differentiated, 159 cases of moderately differentiated and 115 cases of poorly differentiated tumors.

Patients were followed up until August 31, 2012, with an interval of 6 months. The 1-year, 3-year, and 5-year survival rates were 71.7%, 38.2%, and 10.9%, respectively. We next determined the relationship of all observed indexes and postoperative prognosis using log-rank single-factor analysis ([Table 2](#t2-medscimonit-21-2375){ref-type="table"}). Thirteen indexes were significantly correlated (P\<0.05): depth of invasion, lymphatic metastasis, tumor differentiation, TNM staging, resection margin invasion, blood transfusion during surgery, total bilirubin (TBIL), conjugated or direct bilirubin (DBIL), alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transaminase (AST), gamma-glutamyl transpeptidase (GGT), and relapse status ([Table 2](#t2-medscimonit-21-2375){ref-type="table"}).

The risk of death with poor differentiation was 1.356 times that of medium differentiation, while the latter is 1.356 times that of high differentiation. The risk of death increased by 1.379 times as TNM staging increases a level. The risk of death on patients with positive resection margins was 1.404 times that of patients with negative resection margins. Intrahepatic tumors caused a risk of death 0.594 times that of extrahepatic ones. Patients who received blood transfusion during the operation had a risk of death 1.493 times that of those who did not receive a transfusion. Relapsed patients had a risk of death 1.962 times that of those who did not exhibit a relapse. Patients who had high ALP in blood had a risk of death 1.954 times that of those who had normal ALP.

All 13 indexes were used in Cox model regression analysis. With α=0.05, we were able to import independent factors related to cholangiocarcinoma postoperative prognosis because all variables passed the Cox multivariable analysis ([Table 3](#t3-medscimonit-21-2375){ref-type="table"}).

Discussion
==========

The morbidity of cholangiocarcinoma has been increasing in recent years. The prognoses of advanced cholangiocarcinoma cases are very poor, with median survival time less than 1 year \[[@b12-medscimonit-21-2375]\]. Thus, it is imperative to develop comprehensive treatment strategies that consider all 13 factors that affect treatment outcome. Most cholangiocarcinoma patients are diagnosed at an advanced, unresectable stage. Even in those who can receive resection, there is high risk of relapse. We thus performed the initial single-factor analysis, which would allow subsequent multi-factor analysis with a subset of indicator indexes.

As summarized in [Table 2](#t2-medscimonit-21-2375){ref-type="table"}, our analysis revealed 13 indexes that could affect prognosis in cholangiocarcinoma patients. It has been previously shown that portal involvement by hilar cholangiocarcinoma was not a significant contraindication for surgical resection \[[@b13-medscimonit-21-2375]--[@b15-medscimonit-21-2375]\]. Given that most diagnosed cases are in advanced stage of the disease and do not receive surgical resection, it is difficult to investigate the true effect of surgical resection and disease prognosis.

Tumor differentiation status was also previously shown to have significant effect on prognosis \[[@b14-medscimonit-21-2375],[@b15-medscimonit-21-2375]\]. Prognoses are poorer on low-differentiated tumors than on high-differentiated ones. This is mainly because low-differentiated cancers are prone to early metastasis. Our research also shows that prognoses of cancers with low differentiation are poorer than of those with medium or high differentiation. Thus, making sure about the degree of differentiation as early as possible can help in deciding the best treating method. There are 2 possible methods to help in diagnosis: one is preoperative biopsy diagnosis and the other is intraoperative frozen pathological diagnosis.

Tumor stages have also been related with prognosis \[[@b16-medscimonit-21-2375]\]. Early stages indicate that tumors are confined to local metastasis, and late stages indicate that tumors might have already had distant metastasis. Locally-confined tumors are easier to totally resect. However, tumors that have already had distant metastasis are not likely to be totally removed by surgery. Early stages of cholangiocarcinoma do not have obvious clinical manifestation; instead, there could only be jaundice or pruritus. Existence of obvious clinical manifestation means that cholangiocarcinoma is already in advanced stage. Recently, more methods are used to diagnose cholangiocarcinoma. Imaging diagnosis can find cholangiectasis at early stages.

It is widely believed that resection margin infiltrated by cancer cells indicate a poor prognosis \[[@b17-medscimonit-21-2375]\]. A positive resection margin usually indicates that tumor is removed generally, but not a complete cure when examined microscopically. It has been shown that the length of cholangiocarcinoma cells invaded mucosa are usually shorter than 10 mm \[[@b17-medscimonit-21-2375]\]. Thus, surgical resects 10 mm away from the tumor could achieve a non-invaded resection margin.

As we performed single-factor analysis, the statistical tests on tumor location have no statistical interpretation. But when doing multi-factor analysis, tumor location has difference in statistical tests, which indicates multi-factor interaction influences. It has been shown that the 1-year, 3-year, and 5-year survival rates for intrahepatic cholangiocarcinoma are 62%, 24%, and 20%, respectively, and the median survival time is 16.9 months. The 1-year, 3-year and 5-year survival rates for hilar cholangiocarcinoma are 49%, 16%, and 8%, respectively, and the median survival time is 11.7 months \[[@b3-medscimonit-21-2375]\]. Statistical differences exist within the survival time, which corroborates the findings of the current study.

It has been suggested before that intraoperative blood transfusion could increase the chance of relapse of malignant tumors \[[@b18-medscimonit-21-2375]\]. Whether blood transfusion is taken during the operation indicates intraoperative blood loss or preoperative anemia. The exact mechanism by which intraoperative blood transfusion effects prognosis is still not clear, but research shows that blood transfusion could cause immune system adjustment by inhibiting the immune function of recipients and causing a drop in antibody level. Thus, if intraoperative blood transfusion is necessary, autologous transfusion, blood component transfusion, and in-need transfusion are available.

Conclusions
===========

Highly differentiated tumor, early stages of TNM staging, no resection margin invaded, no intraoperative blood transfusion, intrahepatic tumor, normal ALP levels and no relapse are associated with good prognosis of cholangiocarcinoma. Initial results from ongoing clinical trials have indicated that chemotherapy response rate, disease control rate, and overall survival have a significant correlation \[[@b19-medscimonit-21-2375]--[@b23-medscimonit-21-2375]\]. Thus it is imperative to explore adjuvant, neoadjuvant, and first-line chemotherapy to gain understanding and provide reference value for comprehensive treatment strategies for cholangiocarcinoma.
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###### 

Clinicopathological characteristics of the enrolled patients.

  Program                                          Group                                                Patients   Percentage
  ------------------------------------------------ ---------------------------------------------------- ---------- ------------
  Gender                                           Male                                                 202        68.9
  Female                                           91                                                   31.1       
  Age                                              \<64                                                 136        46.4
  ≥64                                              157                                                  53.6       
  Tumor location                                   Intrahepatic                                         74         25.3
  Extrahepatic                                     219                                                  74.7       
  Tumor Size                                       \<3 cm                                               161        54.9
  ≥3 cm                                            132                                                  45.1       
  Depth of Invasion                                Total infiltration                                   167        57.0
  Local infiltration                               126                                                  43.0       
  Lymphatic metastasis                             Yes                                                  51         17.4
  No                                               242                                                  82.6       
  Differentiation                                  High                                                 19         6.5
  Medium                                           159                                                  54.3       
  Low                                              115                                                  39.2       
  Nerve Invasion                                   Yes                                                  93         31.7
  No                                               200                                                  68.3       
  Vascular cancer embolus                          Yes                                                  17         5.8
  No                                               276                                                  94.2       
  TNM Staging                                      I                                                    150        51.2
  II                                               88                                                   30.0       
  III                                              41                                                   14.0       
  IV                                               14                                                   4.8        
  Resection Margin                                 Positive                                             74         25.3
  Negative                                         219                                                  74.7       
  Intraoperative blood loss                        \<500 ml                                             186        63.5
  ≥500 ml                                          107                                                  36.5       
  Blood transfusion                                Yes                                                  89         30.4
  No                                               204                                                  69.6       
  Relapse                                          Yes                                                  158        53.9
  No                                               135                                                  46.1       
  Chemotherapy                                     Yes                                                  4          1.4
  No                                               289                                                  98.6       
  TBIL                                             Normal                                               83         28.3
  High                                             210                                                  71.7       
  DBIL                                             Normal                                               85         29.0
  High                                             208                                                  71.0       
  ALP                                              Normal                                               82         28.0
  High                                             211                                                  72.0       
  ALT                                              Normal                                               82         28.0
  High                                             211                                                  72.0       
  Aspartate Transaminase                           Normal                                               87         29.7
  High                                             206                                                  70.3       
  GGT                                              Normal                                               73         24.9
  High                                             220                                                  75.1       
  Surgical method                                  Not combined with portal vein resection and repair   284        96.9
  Combined with portal vein resection and repair   9                                                    3.1        
  History of hepatitis                             Yes                                                  18         6.1
  No                                               275                                                  93.9       
  Stone                                            Yes                                                  31         10.6
  No                                               262                                                  89.4       
  Cholecystectomy before the illness               Yes                                                  36         12.3
  No                                               257                                                  87.7       

###### 

Single factor analysis for cholangiocarcinoma clinical data and treatment characteristics.

  Factor                                           Group                                                Patients   Median survival time (months)   95%CI            P-value
  ------------------------------------------------ ---------------------------------------------------- ---------- ------------------------------- ---------------- ---------
  Gender                                           Male                                                 202        21.20                           15.629\~26.771   0.981
  Female                                           91                                                   20.67      11.662\~29.678                                   
  Age                                              \<64                                                 136        21.20                           15.649\~26.751   0.585
  ≥64                                              157                                                  20.97      14.108\~27.832                                   
  Tumor location                                   Intrahepatic                                         74         21.20                           11.863\~30.537   0.725
  Extrahepatic                                     219                                                  20.97      15.377\~26.563                                   
  Tumor size                                       \<3 cm                                               161        25.00                           17.225\~32.775   0.328
  ≥3 cm                                            132                                                  17.43      12.146\~22.714                                   
  Depth of invasion                                Total infiltration                                   167        27.47                           17.339\~37.601   0.012
  Local infiltration                               126                                                  15.83      14.078\~17.582                                   
  Lymphatic metastasis                             Yes                                                  51         26.23                           20.032\~32.428   0.000
  No                                               242                                                  14.27      11.711\~16.829                                   
  Differentiation                                  High                                                 19         49.77                           28.916\~70.624   0.001
  Medium                                           159                                                  27.47      19.620\~35.320                                   
  Low                                              115                                                  15.23      13.128\~17.332                                   
  Nerve Invasion                                   Yes                                                  93         17.47                           12.229\~22.711   0.157
  No                                               200                                                  24.03      16.733\~31.327                                   
  Vascular cancer embolus                          Yes                                                  17         14.67                           6.737\~22.603    0.227
  No                                               276                                                  21.50      16.151\~26.849                                   
  TNM staging                                      I                                                    150        37.33                           29.075\~45.585   0.000
  II                                               88                                                   15.67      13.372\~17.968                                   
  III                                              41                                                   16.93      7.232\~26.628                                    
  IV                                               14                                                   7.40       1.955\~12.845                                    
  Resection Margin                                 Positive                                             74         20.67                           14.365\~26.975   0.010
  Negative                                         219                                                  22.40      15.055\~29.745                                   
  Intraoperative blood loss                        \<500 ml                                             186        26.27                           18.545\~33.995   0.199
  ≥500 ml                                          107                                                  15.90      10.131\~21.669                                   
  Blood transfusion                                Yes                                                  89         13.43                           11.037\~15.823   0.001
  No                                               204                                                  27.93      20.505\~35.355                                   
  Relapse                                          Yes                                                  158        18.10                           14.458\~21.742   0.000
  No                                               135                                                  31.50      3.236\~59.764                                    
  Chemotherapy                                     Yes                                                  4          18.10                           0.000\~41.747    0.745
  No                                               289                                                  21.20      16.030\~26.370                                   
  TBIL                                             Normal                                               83         28.93                           15.172\~42.688   0.025
  High                                             210                                                  18.10      14.466\~21.734                                   
  DBIL                                             Normal                                               85         28.93                           15.007\~42.853   0.032
  High                                             208                                                  18.10      14.483\~21.717                                   
  ALP                                              Normal                                               82         36.53                           18.820\~54.240   0.002
  High                                             211                                                  17.43      14.230\~20.630                                   
  ALT                                              Normal                                               82         36.90                           19.399\~54.401   0.002
  High                                             211                                                  18.10      14.105\~21.795                                   
  AST                                              Normal                                               87         30.57                           11.745\~49.395   0.014
  High                                             206                                                  18.13      13.635\~22.625                                   
  GGT                                              Normal                                               73         41.30                           22.698\~59.902   0.003
  High                                             220                                                  17.43      14.034\~20.826                                   
  Surgical method                                  Not combined with portal vein resection and repair   284        20.97                           16.048\~25.892   0.320
  Combined with portal vein resection and repair   9                                                    25.37      0.000\~80.796                                    
  History of hepatitis                             Yes                                                  18         41.30                           15.171\~67.429   0.072
  No                                               275                                                  20.53      16.086\~24.974                                   
  Stone                                            Yes                                                  31         15.90                           11.646\~20.154   0.099
  No                                               262                                                  21.50      16.418\~26.582                                   
  Cholecystectomy before the illness               Yes                                                  36         16.40                           14.783\~18.017   0.243
  No                                               257                                                  21.73      16.743\~26.717                                   

###### 

Multivariable regression analysis of cholangiocarcinoma using Cox proportional hazard model.

  Parameter           Regression parameter estimation (B)   Standard errors (BE)   Wald     Degree of freedom   P-value (Sig)   Relative risk (B)   95% CI for Exp (B)
  ------------------- ------------------------------------- ---------------------- -------- ------------------- --------------- ------------------- --------------------
  Differentiation     0.304                                 0.115                  6.953    1                   0.008           1.356               1.081\~1.699
  TNM staging         0.322                                 0.079                  16.548   1                   0.000           1.379               1.181\~1.610
  Resection margin    0.339                                 0.154                  4.832    1                   0.028           1.404               1.037\~1.899
  Tumor location      −0.520                                0.190                  7.496    1                   0.006           0.594               0.410\~0.863
  Blood transfusion   0.401                                 0.144                  7.704    1                   0.006           1.493               1.125\~1.982
  Relapse             0.674                                 0.149                  20.511   1                   0.000           1.962               1.466\~2.627
  ALP                 0.670                                 0.192                  12.235   1                   0.000           1.954               1.342\~2.844
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